절제 불가능한 췌장암의 고식적 방사선치료 결과 = The Results of Palliative Radiation Therapy in Patients with Unresectable Advanced Pancreatic Cancer

국문 초록 (Abstract)

목 적: 췌장암은 진단 시 절제 불가능한 진행된 병변을 갖는 경우가 많으므로 방사선치료 시 고식적 증상완화의
효과 및 예후를 알아보고 영향을 미치는 인자에 대해 알아보고자 하였다. 대상 및 방법: 1984년 3월부터 2005년 2월까지 가톨릭대학교 강남성모병원에서 통증완화를 위한 고식적 방사선 치료를 받은 절제 불가능한 췌장암 환자 중 추적조사가 가능한 37명을 대상으로 치료결과 및 관련인자에 대하여 후향적 분석을 시행하였다. 환자의 성별은 남자 22명(59.5%), 여자 15명(40.5%)이었으며, 연령은 30세에서 80세 사이로 중앙값 57세였다. 진단 시 12명(32.4%)에서 간전이가 있었고, 22명(59.5%)에서 임파절 전이가 있었다. 방사선 치료는 종양 및 주변 임파절에서 1∼2 cm 범위까지 3,240∼5,580 cGy (중앙값 5,040 cGy)를 조사하였으며, 30명(81%)에서 항암화학요법을 병행하였는데 5-FU (fluorouracil) 단독을 투여한 경우가 21명이었고, 9명에서는 gemcitabine이 단독으로 또는 5-FU와 함께 투여되었다. 추적관찰기간은 1개월에서 44개월이었으며, 생존율 및 예후인자의 분석은 Kaplan-Meier 방법 및 Log-rank test를 이용하였다. 결 과: 전체환자의 평균 생존기간은 11개월, 중앙 생존기간은 8개월이었으며, 1년 생존율은 20%였다. 전체 환자중 33명에서 치료에 대한 반응을 평가할 수 있었는데, 7명(21.2%)에서 양호, 22명(66.7%)에서 보통의 반응을 보여 87.9%의 증상완화율을 나타냈다. 방사선치료의 부작용은 경증 및 중등도의 오심, 구토, 소화불량이 14명(37.8%)에서 나타났으나 치료의 중단을 요하는 중증의 부작용은 관찰되지 않았다. 항암화학요법은 방사선치료와 병행여부에 따라 생존율이나 증상의 고식정도에는 차이가 없는 것으로 나타났으며(p＞0.05), 약제의 종류에 따라 gemcitabine 약제가 주가된 군에서 중앙생존기간이 12개월로 5-FU를 단독으로 투여한 군의 5.5개월보다 높은 것으로 나타났으나 통계적으로 유의한 차이를 보이지는 않았다(p＞0.05). 예후에 영향을 미치는 인자로는 환자의 카르노프스키 활동도, 간전이 유무가 관련이 있는 것으로 나타났으며(p＜0.05), 이외에 성별, 나이, 병변위치, 임파선 전이유무, CA19-9 수치는 관련이 없는 것으로 나타났다(p＞0.05).결 론: 절제 불가능한 췌장암 환자에 있어서 방사선치료는 고식적 증상완화에 효과적이며, gemcitabine과 같은 항암화학요법과 더불어 다른 새로운 약제와 함께 생존율 향상에 역할을 할 것으로 기대되므로 앞으로 이에 대한 많은 연구가 필요할 것이다.

다국어 초록 (Multilingual Abstract)

Purpose: To evaluate the treatment results and prognostic factors of palliative radiation therapy in the patients with unresectable advanced pancreatic cancer. Materials & Methods: Thirty-seven evaluable patients with unresectable advanced pancreatic cancer who were treated by palliative radiation therapy for pain relief at the Department of Radiation Oncology, Kangnam St. Mary's hospital, the Catholic University of Korea between March 1984 and February 2005 were analysed retrospectively. There were 22 men and 15 women. Age at diagnosis ranged from 30 to 80 (median 57) years. Twelve patients (32.4%) had liver metastases and 22 patients (59.5%) had lymph node metastases. Radiation therapy was delivered to primary tumor and regional lymph nodes with 1∼2 cm margin, and total dose was 3,240∼5,580 cGy (median 5,040 cGy). Chemotherapy with radiotherapy was delivered in 30 patients (81%) with 5-FU alone (21 patients) or gemcitabine (9 patients). The follow-up period ranged from 1 to 44 months. Survival and prognostic factors were analysed using Kaplan-Meier method and log-rank test respectively. Results: Overall mean and median survival were 11 and 8 months and 1-year survival rate was 20%. Among 33 patients who were amenable for response evaluation, 7 patients had good response and 22 patients had
fair response with overall response rate of 87.9%. Mild to moderate toxicity were observed in 14 patients with
nausea, vomiting, and indigestion, but severe toxicity requiring interruption of treatment were not observed.
Chemotherapy didn't influence the survival and symptomatic palliation, but the group containing gemcitabine
showed a tendency of longer survival (median 12 months) than 5-FU alone group (median 5.5 months) without
statistical significance (p＞0.05). The significant prognostic factors were Karnofsky performance status and liver metastasis (p＜0.05). Age, sex, tumor location, lymph node metastasis, and CA 19-9 level did not show any
prognostic significance (p＞0.05). Conclusion: Radiation therapy was effective for symptomatic palliation in the patients with unresectable advanced pancreatic cancer and would play an important part in the survival benefit with gemcitabine or other targeted agents.

목차 (Table of Contents)

• 서 론
• 대상 및 방법
• 결 과
• 고 찰

참고문헌 (Reference)

• 1 "Treatment and survival in 13 560 patients with pancreatic cancer and incidence of the disease" 111-115, brjsurg1995
• 2 "Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas" 32 : 1341-1345, 1973
• 3 "Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma" 56 : 2563-2568, 1985
• 4 "Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas" 28 : 227-233, 2005
• 5 "Prognostic indicators for survival after resection of pancreatic adenocarcinoma" 165 : 68-73, 1993
• 6 "Precision radiotherapy for cancer of the pancreas:technique and results" 6 : 1127-1133, 1980
• 7 "Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma" 76 : 48-53, 2005
• 8 "Pancreatic cancer" 16 : 121-124, 2002
• 9 "Pancreatic cancer" 35 : 212-216, 2006
• 10 "Modern management of pancreatic carcinoma" 34 : 475-481, 2004
• 11 "Locally advanced, unresectable pancreatic cancer treated by stereotactic radiation therapy" 24 : 11-20, 2006
• 12 "Locally advanced pancreatic cancer" 23 : 4538-4544, 2005
• 13 "Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer" 40 : 1074-1080, 2004
• 14 "Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer" 57 : 98-104, 2003
• 15 "Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocar- cinoma of the pancreas:a phase III trial of the NationalCancer Institute of Canada Clinical Trials Group" 21 : 3296-3302, 2003
• 16 "Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer" 2 : 865-867, 1969
• 17 "Chemotherapy prolongs survival in inoperable pancreatic carcinoma" 81 : 882-885, 1994
• 18 "Chemotherapy in the treatment of cancer of the pancreas" 5 : 235-241, 1998
• 19 "Cancer statistics 2002" 52 : 23-47, 2002
• 20 "Cancer of the pancreas" Lippincott Williams and Wilkins 1126-1161, 2001
• 21 "Annual report of the central cancer registry in Korea 2004" 2004